Long-term acid inhibition: Benefits and harms

Digestive Diseases

Volumn 29, Issue 5, 2011, Pages 476-481

  Tepeš, Bojan ^a  

^a AM DC Rogaka ^*  (Slovenia)

Author keywords

Bone metabolism; Clopidogrel; Gastric mucosa; Long term acid inhibition; Proton pump inhibitors, side effects

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIUM; CLOPIDOGREL; CYANOCOBALAMIN; IRON; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ARTICLE; BONE METABOLISM; CALCIUM ABSORPTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SUBSTITUTION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; HYPOMAGNESEMIA; INTERSTITIAL NEPHRITIS; INTESTINE ABSORPTION; IRON METABOLISM; OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STOMACH ACID; STOMACH ACID SECRETION; STOMACH MUCOSA; TREATMENT INDICATION;

ANIMALS; BONE AND BONES; GASTRIC ACID; GASTRIC MUCOSA; HUMANS; INTESTINAL ABSORPTION; PROTON PUMP INHIBITORS; TIME FACTORS;

EID: 81755162856     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000331519     Document Type: Article

References (74)

1. IMS Health Report: Leading therapy classes by global pharmaceutical sales 2006. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ StaticFile/Top-Line-Data/Leading%20Therapy%20Class- es%20by%20Global%20Pharmaceutical%20 Sales%202006.pdf.
2. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacoki-netics. Eur J Clin Pharmacol 2008; 64: 935-951.
3. Shin JM, Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 528-534.
4. +-ATPase. Annu Rev Pharmacol Toxi-col 1995; 35: 277-305.
5. Sachs G, Shin JM, Howden CW: Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23(suppl 2):2-8. (Pubitemid 44383831)
6. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54:473-500. (Pubitemid 27395597)
7. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14:651-668. (Pubitemid 30352732)
8. Relly JP: Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56(suppl 4):S11-S17.
9. Geevasinga N, Coleman PL, Webster AC, Roger S: Proton pump inhibitors and acute intestinal nephritis. Clin Gastroenterol Hep-atol 2006; 4: 597-604.
10. Kour y SI, Stone CK, La Charité DD: Omepra-zole and the development of acute hepatitis. Eur J Emerg Med 1998; 5, 467-469.
11. Garcia Rodriges LA, Mannino S, Wallander MA, Lindblom B: A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 1996; 42:213-216. (Pubitemid 26255068)
12. Nardino RJ, Vender RJ, Herbert PN: Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95:3118-3122.
13. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL: Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83:66-68.
14. Nordin BE: Calcium and osteoporosis. Nutrition 1997; 13: 664-686. (Pubitemid 27347169)
15. Sheik MS, Santa Ana CA, Nicar MJ, et al: Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987; 317: 532-536. (Pubitemid 17123269)
16. Graziani G, Como G, Badalamenti S, et al: Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995; 10:1376-1380.
17. Graziani G, Badalamenti S, Como G, et al: Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002; 91: 474-479. (Pubitemid 34765248)
18. Hardy P, Sechet A, Hottelart C, et al: Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998; 22: 569-573. (Pubitemid 28324030)
19. O'Connell MB, Madden DM, Murray AM, et al: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-781. (Pubitemid 40897665)
20. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al: Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14: 364-368.
21. Chorad ME, Shade SG: Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. Gastroenterology 1968; 55:35-45.
22. Bezwoda W, Charlton R, Bothwell T, et al: The importance of gastric hydrochloric acid in the absorption of non-heme food iron. J Lab Clin Med 1978; 92:108-116. (Pubitemid 8384452)
23. Stewart CA, Termanini B, Sutliff VE, et al: Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998; 12:83-98. (Pubitemid 28057410)
24. Epstein M, McGrath S, Law F: Proton-pump inhibitors and hypomagnesemic hypopara-thyroidism. N Engl J Med 2006; 355: 18 3 4-1836.
25. Cundy T, Dissanayake A: Severe hypomag-nesaemia in long-term users of proton pump inhibitors. Clin Endocrinol 2008; 69:338-341. (Pubitemid 352009025)
26. Shabajee N, Lamb EJ, Sturgess I, et al: Omeprazole and refractory hypomagnesae-mia. BMJ 2008; 337:A425.
27. 12 in patients with hypochlorhydria and achlorhydria and after gastric resection. Gastroenterology 1973; 64:913-919.
28. Festen HP: Intrinsic factor secretion and co-balamin absorption. Physiology and patho-physiology in the gastrointestinal tract. Scand J Gastroenterol Suppl 1991; 18 8: 1-7.
29. 12 levels. Aliment Pharmacol Ther 1999; 13: 1343-134 6. (Pubitemid 29462310)
30. Insogna KL: The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009; 104(suppl 2):S2-S4.
31. McColl K E: Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104(suppl 2):S5-S9.
32. +-ATPase, on bone resorption in humans. Cal-cif Tissue Int 1993; 53: 21-25. (Pubitemid 23187327)
33. 12 levels are associated with increased hip bone loss in older women: a prospective study. J Clin Endocrinol Metab-ol 2004; 89:1217-1221. (Pubitemid 38368416)
34. 12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005; 20:152-158. (Pubitemid 41716230)
35. 12 status is a ssociated w it h bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003; 133, 801-807. (Pubitemid 36268358)
36. Sato Y, Honda Y, Iwamoto J, et al: Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293:1082-1088. (Pubitemid 40300282)
37. Yang Y-X, Lewis JD, Epstein S, et al: Long-term proton pump inhibitor therapy and risk of hip fracture. JA M A 2006; 296: 2947-2953. (Pubitemid 46021498)
38. Targownik LE, Lix LM, Metge CJ, et al: Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-32 6.
39. Kaye JA, Jick H: Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-959.
40. Targownik LE, Lix LM, Leung S, et al: Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterolog y 2010; 138: 896-904.
41. Laheij RJ, Sturkenboom MC, Hassing RJ, et al: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955-1960. (Pubitemid 39411203)
42. Theisen J, Nehra D, Citron D, et al: Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjuga-tion of bi le acids. J Ga strointe st Su rg 2000; 4: 50-54.
43. Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955-1960.
44. Gulmez SE, Holm A, Frederiksen H, et al: Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 16 7: 950-955. (Pubitemid 46762758)
45. Sarkar M, Hennessy S, Yang YX, et al: Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 14 9: 391-398.
46. Wilcox MH, Mooney L, Bendall R, et al: A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62: 388-396. (Pubitemid 351984787)
47. Elphick DA, Chew TS, Higham SE, et al: Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? Gerontolog y 2005; 51: 396-4 01. (Pubitemid 41675013)
48. Leonard J, Marshall JK, Moayyedi P: Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gas-troenterol 2007; 102:2047-2056. (Pubitemid 47301504)
49. El-Zimaity HM, Jackson FW, Graham DY: Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92:1858-1860. (Pubitemid 27440906)
50. Raghunath AS, O'Morain C, McLoughlin RC: Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 20 05; 2 2(suppl 1):55-63. (Pubitemid 41153080)
51. Uemura N, Okamoto S, Yamamoto S, et al: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. A liment Pharmacol Ther 2000; 1 4: 13 4 5-1352.
52. European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
53. Tepes B, Kavcic B, Zaletel-Kragelj L, et al: Two-to four-year histologic follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 18 8: 24-29. (Pubitemid 29197310)
54. Sung JJ, Lin SR, Ching JY: Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective randomized study. Gastroenterology 2000; 119:7-14. (Pubitemid 30452573)
55. Rocco A, Suriani R, Cardesi E, et al: Gastric atrophy and intestinal metaplasia changes 8 years after Helicobacter pylori eradication. A blind, randomized study. Minerva Gastro-enterol Dietol 2002; 48:175-178.
56. Ito M, Haruma K: Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 1449-1456. (Pubitemid 34953585)
57. Solcia E, Fiocca R, Havu N, et al: Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51(suppl 1):82-92.
58. Genta RM, Rindi G, Fiocca R, et al: Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003; 98:1257-1265. (Pubitemid 36741519)
59. Wang TC, Koh TJ, Varro A, et al: Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996; 98: 1918-1929. (Pubitemid 26359210)
60. Robertson DJ, Larsson H, Friis S, et al: Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-760. (Pubitemid 47385871)
61. Singh M, Dhindsa G, Friedland S, Triadafi-lopoulos G: Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther 2007; 26: 1051-10 61. (Pubitemid 47416294)
62. Van Soest EM, van Rossum LG, Dieleman JP, et al: Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966-973. (Pubitemid 351501082)
63. Ishiazaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(suppl 3):27-36. (Pubitemid 29389409)
64. Gurbel PA, Antonio MJ, Tantry US: Recent developments in clopidogrel pharmacology and their relation to clinical outcome. Expert Opin Drug Metab Toxicol 2009; 5:989-1004.
65. Gilard M, Arnaud B, Cornily JC, et al: Influence of omepra zole on t he antiplatelet act ion of clopidogrel associated with aspirin. J Am Coll Ca rdiol 20 08; 51: 256-260.
66. Angiolillo DJ, Gibson CM, Cheng S, et al: Differential effects of omeprazole and pan-toprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled crossover comparison studies. Clin Pharmacol Ther 2011; 89:65-74.
67. Gupta E, Bansal D, Sotos J, Olden K: Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2009; 55: 196 4-1968.
68. Ho PM, Maddox TM, Wing L, et al: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-94 4.
69. Juurlink DN, Gomes T, Ko DT, et al: A population-based study of the drug interaction between proton pump inhibitors and clopi-dogrel. CMAJ 20 09; 18 0: 713-718.
70. Pezalla E, Day D, Pulliadath I: Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52:1038-1039.
71. Rassen JA, Choudhry NK, Avorn J, Schnee-weiss S: Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120:2322-2329.
72. Kwork CS, Loke YK: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810-8 2 3.
73. O'Donoghue ML, Braunwald E, Antman EM, et al: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
74. Bhatt DL, Cryer BL, Contant CF, Cohen M, et al: Clopidogrel with or without omepra-zole in coronary arter y disease. N Engl J Med 2010; 363: 19 09-1917.